media article on viralytics, page-16

I'll have a good read TassieTwo and if I figure it out I'll get back to you. On the poster for the melanoma trials the first sentence of the introduction seems to be the crucial point being made i.e "During numerous clinical evaluations of oncolytic viruses (virotherapy), the host immune system is constantly questioned as to playing a "friend or foe" role in potential efficacy outcomes."
It's still concerning Phase 1 trial and they were pleased with the results so I guess this presentation is just to give the medicos some details.
Hopefully someone else can come along and explain it better. I haven't read the other presentation yet.